Tango Therapeutics (TNGX) Net Cash Flow (2020 - 2026)

Tango Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $45.1 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 506.57% year-over-year to $45.1 million in Q1 2026; TTM through Mar 2026 was $99.0 million, a 3723.87% increase from a year earlier, with the FY2025 full-year figure at $42.7 million, up 1767.58% from the prior year.
• Net Cash Flow retreated to $45.1 million in Q1 2026 per TNGX's latest filing, from $53.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $53.9 million in Q4 2025 and bottomed at -$41.1 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$3.3 million (2023), against an average of $879000.0.
• Across the five-year window, Net Cash Flow sank 209.93% in 2022 and soared 1105.18% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$40.3 million in 2022, then jumped by 119.46% to $7.9 million in 2023, then jumped by 108.63% to $16.4 million in 2024, then surged by 229.27% to $53.9 million in 2025, then retreated by 16.35% to $45.1 million in 2026.
• Per Business Quant, the three latest TNGX Net Cash Flow figures stand at $45.1 million (Q1 2026), $53.9 million (Q4 2025), and $19.1 million (Q3 2025).